Partnership Applications Now Open
Washington, DC – March 7, 2022 – Global Liver Institute (GLI) will convene the fifth International NASH Day (#NASHday) on June 9, 2022 with the theme Stop NASH Now. This year, GLI is pleased to support grassroots efforts from around the globe that will raise awareness and promote diagnosis and care options in ways as unique as each community. Held annually on the second Thursday in June, #NASHDay exists to increase awareness about nonalcoholic steatohepatitis (NASH) among at-risk patients, medical professionals, and the global public health community.
“International NASH Day annually advances the global movement to prevent and treat NASH. It is the premier collaboration of community leaders, healthcare providers, and industry, informed by the patient voice,” stated Donna R. Cryer, JD, president and CEO of GLI. “Across the globe there is an immediate need to relieve the heavy burden that NASH places on every community. It is time to Stop NASH Now.”
GLI has opened applications from non-profit organizations to become 2022 #NASHDay partners and Stop NASH NOW through local outreach or participation in virtual program options. Among a number of benefits, partners will be provided with multilingual NAFLD/NASH educational materials that they may use, and a limited number may receive program-support grants. Learn more about partner benefits and requirements and submit your application by April 15, 2022.
Annually, GLI aligns and advances the global conversation around NASH by convening international panelists of experts on relevant topics, from innovations in non-invasive diagnostics to the connection between NASH and cardiometabolic diseases. However, the strength of #NASHDay each year comes in large part from the action and creativity of each partner organization involved. NASH is the advanced form of nonalcoholic fatty liver disease (NAFLD). Both are closely linked with obesity, and current global estimates show that as many as 25-30% of people have NAFLD and 2–6% have NASH.1 2 While the symptoms of NASH affect patients throughout the world in a similar manner, every community has different values and resources to consider for prevention and treatment. The culturally relevant programming of each #NASHday partner is critical to its impact.
Last year, GLI and its 120 #NASHday partners around the world organized engaging digital events to declare the urgency of combating NASH in their communities. Many organizations sent representatives to speak on local TV or radio talk shows, while some facilitated training days on NASH diagnosis and treatment options and even coordinated mobile clinic visits to neighborhoods. Join advocates from around the globe and become a 2022 #NASHday partner to Stop NASH Now!
For additional information on International NASH Day, visit www.international-nash-day.com
To become a partner, please submit the application, partner agreement forms, and budget request form (if requesting support) online at https://www.international-nash-day.com/partner-application.
Support the NASH Daysocial media campaign using hashtags #NASHday #StopNASHNowPlease direct any additional questions to NASHDay@globalliver.org.
International NASH Day and its logo are registered trademarks of Global Liver Institute.
# # #
About Global Liver Institute
Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube. GLI is the global host of International NASH Day.
(1) Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology (Baltimore, Md.), 67(1), 123–133. https://doi.org/10.1002/hep.29466
(2) Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016). Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, Md.), 64(1), 73–84. https://doi.org/10.1002/hep.28431